Gilead-Merck detail Phase 3 HIV data, Dimension Capital closes $800M fund, WuXi AppTec fights DoD blacklist bid, and more.
July 21, 2026 11:30 AM EDTUpdated 11:48 AM
Gilead and Merck provide HIV data; Dimension Capital announces $800M fund
Gilead and Merck’s HIV data: The duo will present more detailed results of the Phase 3 trials of their once-weekly oral …
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
Think we're worth reading - tell Google.
Detailed phase 3 results suggest the two-drug combination of Gilead Sciences’ lenacapavir and Merck & Co.’s islatravir has what…
Gilead & Merck Phase 3 data shows once-weekly ISL/LEN matches daily HIV meds in viral suppression through 48 weeks.
Trodelvy's latest setback carries implications for a newly important Merck drug, while the success of a once-weekly HIV tablet…
A combination of Merck’s islatravir and Gilead’s lenacapavir has
Gilead and Merck Announce Positive Topline Results From Two Phase 3 Studies Evaluating Islatravir/Lenacapavir, an Oral…
Following in the footsteps of Gilead Sciences, Merck & Co. | Following in the footsteps of Gilead, Merck has signed voluntary…
